Will Pradaxa take the lead in the NOAC treatment market by the health insurance expansion?

The insurance benefit range of the new oral anti-coagulant (NOAC) ‘Pradaxa(generic name: dabigatran)’ will be expanded from the 1^st.

Through the expansion, the drug will not only have the enlarged amount of benefits, but also shorten the benefit range with ‘Xarelto (generic name: rivaroxaban)’ to increase competitiveness against its competing treatment.

The Ministry of Health and Welfare anno...